Publicação: Severe forms of neurocysticercosis: Treatment with albeimdazole
dc.contributor.author | Agapejev, Svetlana [UNESP] | |
dc.contributor.author | Da Silva, Maria Dorvalina | |
dc.contributor.author | Ueda, Anete K. | |
dc.contributor.institution | Universidade de São Paulo (USP) | |
dc.contributor.institution | Universidade Estadual Paulista (Unesp) | |
dc.date.accessioned | 2014-05-27T11:18:04Z | |
dc.date.available | 2014-05-27T11:18:04Z | |
dc.date.issued | 1996-03-01 | |
dc.description.abstract | Study of 22 patients with the severe form of neurocysticercosis treated with albendazole (ABZ) administered in 6 different schedules ranging from 15 to 30 mg/kg/day for 21 to 60 days. Dextrochloropheniramine and ketoprofen were the adjuvant drugs Multiple symptoms were observed in 90 9% of patients. Intracranial hypertension was manifested in 90.9%. Hydrocephaly occurred in 86.4%. Evolution was satisfactory in 10 patients, 8 died and 4 had sequelae. Tomographic studies showed the appearance of an isolated IVth ventricle in 9 patients, after ventriculoperitoneal shunt, before ABZ treatment in 3 of them, during in 5 and after treatment in one. Median clinical follow-up duration was 10 months for the patients who died and 3-4 years for survivors. In 3 patients there was an increase in cyst size during the administration of the 15 mg/kg/day ABZ dose, which was not observed in any patient when the 30 mg/kg/day dose was used. | en |
dc.description.affiliation | Division of Neurology Botucatu School of Medicine State University of São Paulo | |
dc.description.affiliation | Dept. of Neurology and Psychiatry School of Medicine UNESP, P.O Box 540, 18618-000 Botucatu SP | |
dc.description.affiliationUnesp | Dept. of Neurology and Psychiatry School of Medicine UNESP, P.O Box 540, 18618-000 Botucatu SP | |
dc.format.extent | 82-93 | |
dc.identifier | http://dx.doi.org/10.1590/S0004-282X1996000100014 | |
dc.identifier.citation | Arquivos de Neuro-Psiquiatria, v. 54, n. 1, p. 82-93, 1996. | |
dc.identifier.doi | 10.1590/S0004-282X1996000100014 | |
dc.identifier.file | 2-s2.0-0029965675.pdf | |
dc.identifier.issn | 0004-282X | |
dc.identifier.scielo | S0004-282X1996000100014 | |
dc.identifier.scopus | 2-s2.0-0029965675 | |
dc.identifier.uri | http://hdl.handle.net/11449/64750 | |
dc.identifier.wos | WOS:A1996TZ93500014 | |
dc.language.iso | eng | |
dc.relation.ispartof | Arquivos de Neuro-Psiquiatria | |
dc.relation.ispartofjcr | 1.015 | |
dc.rights.accessRights | Acesso aberto | |
dc.source | Scopus | |
dc.subject | Albendazole | |
dc.subject | Cysticercosis | |
dc.subject | Dextrochloropheniramine | |
dc.subject | Ketoprofen | |
dc.subject | Neurocysticercosis | |
dc.subject | Severe forms | |
dc.subject | Treatment | |
dc.subject | acetazolamide | |
dc.subject | albendazole | |
dc.subject | dexchlorpheniramine | |
dc.subject | ketoprofen | |
dc.subject | mannitol | |
dc.subject | adolescent | |
dc.subject | adult | |
dc.subject | clinical article | |
dc.subject | drug efficacy | |
dc.subject | female | |
dc.subject | human | |
dc.subject | male | |
dc.subject | neurocysticercosis | |
dc.subject | Adolescent | |
dc.subject | Adult | |
dc.subject | Anthelmintics | |
dc.subject | Brain Diseases | |
dc.subject | Chlorpheniramine | |
dc.subject | Female | |
dc.subject | Follow-Up Studies | |
dc.subject | Humans | |
dc.subject | Male | |
dc.subject | Middle Aged | |
dc.subject | Prognosis | |
dc.subject | Tomography, X-Ray Computed | |
dc.title | Severe forms of neurocysticercosis: Treatment with albeimdazole | en |
dc.type | Artigo | |
dcterms.license | http://www.scielo.br/revistas/anp/paboutj.htm | |
dspace.entity.type | Publication | |
unesp.campus | Universidade Estadual Paulista (Unesp), Faculdade de Medicina, Botucatu | pt |
unesp.department | Neurologia, Psicologia e Psiquiatria - FMB | pt |
Arquivos
Pacote Original
1 - 1 de 1